DK0762892T3 - Difteritoksinvacciner, der bærer et muteret R-domæne - Google Patents

Difteritoksinvacciner, der bærer et muteret R-domæne

Info

Publication number
DK0762892T3
DK0762892T3 DK95921528T DK95921528T DK0762892T3 DK 0762892 T3 DK0762892 T3 DK 0762892T3 DK 95921528 T DK95921528 T DK 95921528T DK 95921528 T DK95921528 T DK 95921528T DK 0762892 T3 DK0762892 T3 DK 0762892T3
Authority
DK
Denmark
Prior art keywords
diphtheria toxin
mutated
domain
vaccines carrying
toxin vaccines
Prior art date
Application number
DK95921528T
Other languages
Danish (da)
English (en)
Inventor
David Eisenberg
R John Collier
Wei Hai Shen
Seunghyon Choe
Original Assignee
Harvard College
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Univ California filed Critical Harvard College
Application granted granted Critical
Publication of DK0762892T3 publication Critical patent/DK0762892T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK95921528T 1994-06-08 1995-05-31 Difteritoksinvacciner, der bærer et muteret R-domæne DK0762892T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/257,781 US5917017A (en) 1994-06-08 1994-06-08 Diphtheria toxin vaccines bearing a mutated R domain

Publications (1)

Publication Number Publication Date
DK0762892T3 true DK0762892T3 (da) 2006-06-19

Family

ID=22977726

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95921528T DK0762892T3 (da) 1994-06-08 1995-05-31 Difteritoksinvacciner, der bærer et muteret R-domæne

Country Status (10)

Country Link
US (1) US5917017A (de)
EP (1) EP0762892B1 (de)
JP (1) JP3755773B2 (de)
AT (1) ATE317701T1 (de)
CA (1) CA2191239A1 (de)
DE (1) DE69534786T2 (de)
DK (1) DK0762892T3 (de)
ES (1) ES2258768T3 (de)
PT (1) PT762892E (de)
WO (1) WO1995033481A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
WO1998039425A2 (en) * 1997-03-05 1998-09-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectors and methods for expression of mutant proteins
CA2284079C (en) 1997-03-05 2009-05-12 David M. Neville Immunotoxins and methods of inducing immune tolerance
JP2003531841A (ja) * 2000-05-04 2003-10-28 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 微生物感染の治療と予防のための化合物と方法
JP4870895B2 (ja) 2000-06-29 2012-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2002020059A2 (en) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002040499A1 (en) * 2000-11-14 2002-05-23 Morphotek Inc. A method for generating genetically altered antigens
US8574596B2 (en) 2003-10-02 2013-11-05 Glaxosmithkline Biologicals, S.A. Pertussis antigens and use thereof in vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
DK3017827T3 (en) 2005-12-22 2019-02-18 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate VACCINE
PT2004225E (pt) 2006-03-22 2012-05-30 Novartis Ag Regimes para imunização com conjugados meningocócicos
EP2056871B1 (de) 2006-08-07 2017-11-15 President and Fellows of Harvard College Proteinmatriximpfstoffe sowie verfahren zur herstellung und verabreichung dieser impfstoffe
ES2387582T3 (es) 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio
EP2142211A1 (de) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Impfstoff
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
EP2349209A2 (de) * 2008-09-26 2011-08-03 Nanobio Corporation Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP6296536B2 (ja) 2010-11-05 2018-03-20 メドベット サイエンス ピーティーワイエルティーディーMedvet Science Pty Ltd 内皮前駆細胞のマーカーおよびその使用
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
FR2988393B1 (fr) * 2012-03-20 2014-05-09 Commissariat Energie Atomique Inhibiteur de l'hb-egf derive du domaine r de la toxine diphterique pour le traitement des maladies associees a l'activation de la voie hb-egf/egfr
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
SG11201506858SA (en) 2013-03-08 2015-09-29 Crucell Holland Bv Acellular pertussis vaccine
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
MX2016009470A (es) 2014-01-21 2017-01-18 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos.
US10105431B2 (en) 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR122023022294A2 (pt) 2014-01-21 2023-12-12 Pfizer Inc. Uso de uma composição imunogênica que compreende um conjugado imunogênico compreendendo um polissacarídeo capsular isolado de streptococcus pneumoniae do sorotipo 15b
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
US10653764B2 (en) 2015-01-15 2020-05-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
RU2021109510A (ru) 2015-12-04 2021-04-16 Дана-Фарбер Кэнсер Инститьют, Инк. Вакцинация с использованием альфа 3 домена mica/b для лечения рака
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3570879B1 (de) 2017-01-20 2022-03-30 Pfizer Inc. Immunogene zusammensetzung zur verwendung als pneumokokken-impfstoff
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
EP3576759A4 (de) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. Verfahren zur herstellung von kapselpolysaccharidproteinkonjugaten aus streptococcus pneumoniae serotyp 19f
EP3585803A4 (de) * 2017-02-24 2020-11-11 Merck Sharp & Dohme Corp. Pneumokokkenkonjugatimpfstoffformulierungen
EP3638301A1 (de) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Behandlungsverfahren
JP7438102B2 (ja) 2017-09-07 2024-02-26 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体-キャリアタンパク質コンジュゲートでのその使用
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
MX2021000548A (es) 2018-07-19 2021-07-02 Glaxosmithkline Biologicals Sa Procesos para preparar polisacáridos en seco.
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム O-結合型グリコシル化のための修飾キャリアタンパク質
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CA3123414A1 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3129425A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体-タンパク質コンジュゲート組成物およびその使用方法
US20220401544A1 (en) 2019-09-27 2022-12-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4051696A1 (de) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia-zusammensetzungen und verfahren dafür
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4240410A1 (de) 2020-11-04 2023-09-13 Pfizer Inc. Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) * 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DE69324487T2 (de) * 1992-05-06 1999-08-12 Harvard College Rezeptorbindende region des diphtherietoxius
EP0652758B1 (de) * 1992-06-18 2000-01-05 The President And Fellows Of Harvard College Impfstoffe gegen diphtherietoxin
US5733726A (en) * 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)

Also Published As

Publication number Publication date
CA2191239A1 (en) 1995-12-14
JP3755773B2 (ja) 2006-03-15
US5917017A (en) 1999-06-29
ATE317701T1 (de) 2006-03-15
EP0762892B1 (de) 2006-02-15
PT762892E (pt) 2006-07-31
EP0762892A4 (de) 1999-06-02
EP0762892A1 (de) 1997-03-19
DE69534786T2 (de) 2006-11-09
WO1995033481A1 (en) 1995-12-14
JPH10502523A (ja) 1998-03-10
ES2258768T3 (es) 2006-09-01
DE69534786D1 (de) 2006-04-20

Similar Documents

Publication Publication Date Title
DK0762892T3 (da) Difteritoksinvacciner, der bærer et muteret R-domæne
DE69733610D1 (de) Interleukin-15 antagoniste
ATE188508T1 (de) Impfstoffe gegen diphtherietoxin
NO2006005I2 (no) Difteri-,tetanus-, acellulære kikhoste- og polioantigener
NO944019L (no) Karboksamid-modifiserte polyamin-chelatorer og radioaktive komplekser og konjugater
NO921926D0 (no) Broennsement med forbedrede egenskaper og fremgangsmaater ved anvendelse
NO971764L (no) Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse
DK0732937T3 (da) Ikke-toxisk slimhindeadjuvans
DE59105320D1 (de) Absperrventileinrichtung.
NO913809L (no) Fremgangsmaate og innretning for aa lette roerperforeringer.
NO880676L (no) Anordning og fremgangsmaate for optimalisering av forbrenning i aapne kammerovner for brenning av karbonblokker.
NO913104D0 (no) Fremgangsmaate for aa redusere friksjon i en gassroerledning.
NO914261L (no) Bindemiddelsammensetning basert paa en akrylatpolymer og et tverrbindingsmiddel basert paa en aceto-acetatforbindelse
NO915105D0 (no) Organiske kopolymerer, fremgangsmaate for deres fremstilling og anvendelse
KR920700816A (ko) 슬라이딩 게이트 밸브, 방법 및 대체가능한 내화물
DE68919101T2 (de) Gasabschaltungsvorrichtung.
DE69010222D1 (de) Magnetooptisches Plattengerät.
SE9501067D0 (sv) New peptides
NO860344L (no) Vevskultur og fremstilling i permeable geler.
DE68922152T2 (de) Kohlenmonoxidcopolymere.
EP0836480A4 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität ausweisen und methoden für ihre herstellung und die verwendung derselben
DE69102120D1 (de) Absperrvorrichtung.
ITTO910697A1 (it) Enzima immobilizzato, relativo procedimento di preparazione ed impiego
DK497788A (da) N-(substitueret alkyliden)-kondenserede bicycloalkyliden og heteroalkyliden-quinolinaminer, deres fremstilling og anvendelse
MX9605651A (es) Nuevos peptidos con efectos inmunorreguladores.